Iqvia Holdings Inc. (IQV) · Oct 27, 2026 · Earnings
Beat — Adjusted EPS $3.34 vs ~$3.26 consensus
IQVIA’s Q3 earnings beat consensus, with stronger clinical demand and another full-year guidance increase reinforcing its recovery story.
IQVIA is in the middle of a demand recovery in outsourced clinical research and healthcare intelligence, while pushing deeper into AI-enabled data and workflow tools. The backdrop was already improving: second-quarter guidance had been raised, and published Q3 expectations called for roughly $4.37 billion of revenue and $3.26 of adjusted EPS.
| Metric | Q3 2026 | Q3 2025 | Versus expectation / change |
|---|---|---|---|
| Revenue | $4.428B | $4.100B | ~$4.37B consensus; +8.0% reported |
| Adjusted EBITDA | $1.032B | $949M | +8.7% |
| Adjusted diluted EPS | $3.34 | $3.00 | ~$3.26 consensus; +11.3% |
| Free cash flow | $667M | $772M | 120% of adjusted net income |
| FY26 revenue guidance | $17.35B–$17.50B | — | Previously $17.275B–$17.475B |
| FY26 adjusted EBITDA guidance | $4.025B–$4.055B | — | Previously $4.00B–$4.05B |
| FY26 adjusted diluted EPS guidance | $12.90–$13.00 | — | Previously $12.80–$13.00 |
The quarter cleared a market bar that was already rising. Revenue was about $58 million above consensus and adjusted EPS about $0.08 above consensus, while both major operating segments grew at roughly 7%–9%. The company’s reported growth was not just an earnings-per-share artifact: Commercial Solutions grew 7.9% at constant currency and R&DS grew 9.1% at constant currency. “Revenue for the third quarter of $4,428million increased 8.0% on a reported basis and 8.6% at constant currency, compared to the third quarter of 2025.”
The more important change is another upward reset to the full-year outlook. IQVIA raised the midpoint of revenue guidance by $50 million, EBITDA by $15 million and adjusted EPS by $0.05, despite the quarter already being expected to land near the top of its prior range. That is a modest raise, but it confirms that the improvement is translating into estimates rather than remaining only in bookings commentary. “The company is raising its full-year 2026 guidance for revenue to be between $17,350million and $17,500million, for Adjusted EBITDA to be between $4,025million and $4,055million and for Adjusted Diluted Earnings per Share to be between $12.90and $13.00.”
Clinical demand is providing the strongest evidence that the recovery is broadening. Management said win rates improved and quarterly clinical bookings were the strongest since 2022, while next-twelve-month R&DS backlog revenue is expected to grow 10% year over year. That matters more than the headline backlog balance because IQVIA also disclosed a previously discussed $2.1 billion cleanup of inactive trials; the adjustment does not change guidance, book-to-bill or next-twelve-month backlog conversion. “The adjustment has no impact on historical financial results, 2026 guidance, book-to-bill, or next-twelve-month revenue from backlog estimates.” 〔0〕
Cash generation improved year to date, but leverage remains part of the story. Nine-month operating cash flow rose to $2.001 billion from $1.919 billion and free cash flow reached $1.518 billion, while net leverage fell from 3.59x at June 30 to 3.45x at September 30. The business is therefore funding acquisitions and buybacks from substantial cash generation, but it still carries $13.818 billion of net debt and expects acquisitions to contribute 250 basis points to the new revenue outlook.
Bottom line: This is more than a routine earnings beat: stronger execution, improving clinical demand and a second guidance increase reinforce IQVIA’s recovery trajectory. The backlog cleanup keeps the headline backlog number noisy, but it does not undermine the near-term revenue outlook in this filing.
Investor Day, December 1, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!